Evidence map›Paper›PMID 38429134›Full record

ReviewTrends in pharmacological sciences2024

VMAT structures reveal exciting targets for drug development.

Shimon Schuldiner, Lucy R Forrest

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Shimon SchuldinerDepartment of Biological Chemistry, Institute of Life Sciences, Silberman Bldg. 1-513, Edmond J. Safra Campus, Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel. Electronic address: shimon.schuldiner@mail.huji.ac.il.
Lucy R ForrestComputational Structural Biology Section, 35 Convent Drive, Room 3D-991, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-8202, USA. Electronic address: lucy.forrest@nih.gov.
Hebrew University of Jerusalem · ILNational Institutes of Health · US

Funding

Computational Studies of Membrane Transport ProteinsZIANS003139 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI FORREST, LUCY · 2014 to 2025
$13.7M
MOLECULAR MECHANISM OF ACTIVE NEUROTRANSMITTER TRANSPORTR01NS016708 · NINDS · HEBREW UNIVERSITY OF JERUSALEM · PI KANNER, BARUCH I, SCHULDINER, SHIMON · 1985 to 2014
$3.0M
Mechanisms of Active Neurotransmitter TransportR56NS016708 · NINDS · HEBREW UNIVERSITY OF JERUSALEM · PI KANNER, BARUCH I, SCHULDINER, SHIMON · 2009 to 2009
$306k
Intramural NIH HHS ZIA NS003139NINDS NIH HHS R01 NS016708NINDS NIH HHS R56 NS016708
6 · The paper itself

Abstract

Vesicular monoamine transporter (VMAT)-2 has a crucial role in the neurotransmission of biogenic amines. Recently, Dalton et al., Pidathala et al., Wu et al., and Wang et al. individually reported cryo-electron microscopy (EM) structures of human VMAT2, offering opportunities for developing improved therapeutics and deep insights into the functioning of this protein.

Indexed as

Cryoelectron MicroscopyDrug DevelopmentVesicular Monoamine Transport ProteinsAnimalsHumansSLC18A2 protein, humanVesicular Monoamine Transport Proteinscryo-EM structureneurotransmissionneurotransmitter transportersynaptic vesicles

Identifiers

PMID38429134
PMCPMC11191364
OpenAlexW4392300880

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.